Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, announced the closing of a $60 million Series A funding to advance its novel tNova platform and deliver therapies to patients faster than ever before.
The round was led by Madrona Venture Group, with participation from a broad syndicate of new and existing investors, including Two Sigma Ventures, Digitalis Ventures, KdT Ventures, Goldcrest Capital, XTX Ventures, Sahsen Ventures, Greentrail Capital, and Alexandria Venture Investments.
The financing will be used to advance the Company's preclinical pipeline of therapeutics and the Company's discovery partnerships.
Company: Terray Therapeutics
Raised: $60.0M
Round: Series A
Funding Month: February 2022
Lead Investors: Madrona Venture Group
Additional Investors: Two Sigma Ventures, Digitalis Ventures, KdT Ventures, Goldcrest Capital, XTX Ventures, Sahsen Ventures, Greentrail Capital, and Alexandria Venture Investments.
Company Website: https://terraytx.com/
Software Category: AI-powered drug discovery
About the Company: Terray Therapeutics is an emerging biotechnology company led by pioneers and long-time leaders in AI, synthetic chemistry, automation, and nanotechnology to propel drug discovery into the information age. Terray's proprietary integrated computational and experimental platforms generate massively scaled, powerfully agnostic chemical data that are purpose-built to power computational learning and reveal new interactions. This foundation is building an iterative, flexible chemistry engine that delivers more precise therapies to patients faster than ever before.
Source: https://www.prnewswire.com/news-releases/terray-therapeutics-launches-with-60m-to-deliver-premium-chemical-data-at-unrivaled-scale-unlocking-the-potential-of-ai-driven-small-molecule-drug-discovery-301481953.html